Aims Some barriers seem to exist in changing implantable cardioverter defibrillator (ICD) manufacturer at the time of device replacement. We sought to understand the obstacles to changing ICD manufacturer within the cohort of patients enrolled in the Detect Long-term Complications After ICD Replacement Registry. Methods We analyzed 784 consecutive ICD/cardiac resynchronization therapy defibrillator (CRT-D) device replacements within a 1.5-year time-frame in 36 Italian centers to evaluate potential factors associated with changing manufacturers and system-related complications. Results Manufacturer change occurred in 191 patients (24%): 72/211 single-chamber ICDs (34%), 52/210 dual-chamber ICDs (25%) and 67/363 CRT-D (18%, P < 0.0001 vs. ...
Background: The patient characteristics, therapy received and outcomes after one or more implantable...
Background: Recently, the Food and Drug Administration issued a recall for the subcutaneous implanta...
Introduction: Comparison data on management of device-related complications and their impact on pati...
Aims: The benefit of prolonged implantable cardioverter-defibrillator (ICD)/cardiac resynchronizatio...
Background: Long-term data on device-related untoward events in patients receiving defibrillators fo...
The replacement of implantable cardioverter-defibrillators (ICDs) may give rise to considerable clin...
AimsThe long-term impact of implantable device-related complications on the patient outcome has not ...
BackgroundThe transvenous implantable cardioverter‐defibrillator (ICD) lead is the most common sourc...
Background: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement...
Aim: Ventricular tachycardia (VT)/ventricular fibrillation (VF) occurrence after cardiac resynchroni...
Background: Implantable cardioverter-defibrillators (ICDs) are widely employed for the prevention of...
Background—Long-term data on device-related untoward events in patients receiving defibrillators for...
AIM: Ventricular tachycardia (VT)/ventricular fibrillation (VF) occurrence after cardiac resynchroni...
Background: The patient characteristics, therapy received and outcomes after one or more implantable...
Background: Recently, the Food and Drug Administration issued a recall for the subcutaneous implanta...
Introduction: Comparison data on management of device-related complications and their impact on pati...
Aims: The benefit of prolonged implantable cardioverter-defibrillator (ICD)/cardiac resynchronizatio...
Background: Long-term data on device-related untoward events in patients receiving defibrillators fo...
The replacement of implantable cardioverter-defibrillators (ICDs) may give rise to considerable clin...
AimsThe long-term impact of implantable device-related complications on the patient outcome has not ...
BackgroundThe transvenous implantable cardioverter‐defibrillator (ICD) lead is the most common sourc...
Background: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement...
Aim: Ventricular tachycardia (VT)/ventricular fibrillation (VF) occurrence after cardiac resynchroni...
Background: Implantable cardioverter-defibrillators (ICDs) are widely employed for the prevention of...
Background—Long-term data on device-related untoward events in patients receiving defibrillators for...
AIM: Ventricular tachycardia (VT)/ventricular fibrillation (VF) occurrence after cardiac resynchroni...
Background: The patient characteristics, therapy received and outcomes after one or more implantable...
Background: Recently, the Food and Drug Administration issued a recall for the subcutaneous implanta...
Introduction: Comparison data on management of device-related complications and their impact on pati...